Literature DB >> 32413742

Hederacoside-C protects against AGEs-induced ECM degradation in mice chondrocytes.

Hai-Chao Xu1, Bin Wu2, Yi-Ming Ma1, Hao Xu1, Zhong-Hai Shen2, Sheng Chen1.   

Abstract

Hederacoside-C (HDC), a natural compound extracted from the leaves of Hedera helix with inflammation modulatory properties in variety of disorders. In this study, we investigated the latent mechanism of HDC in alleviating of the progress of OA in vitro experiment. The results showed that HDC pretreatment suppressed the advanced glycation end-products (AGEs) induced over-regulation of ROS level and inflammatory factors. Moreover, HDC also downregulate the degradation of ECM induced by AGEs. Mechanistically, the HDC suppressed NF-κB signaling pathway in chondrocyte. To sum up, this study indicated HDC possessed a new potential therapeutic option in osteoarthritis.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AGEs; Chondrocytes; Hederacoside-C

Mesh:

Substances:

Year:  2020        PMID: 32413742     DOI: 10.1016/j.intimp.2020.106579

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  3 in total

1.  Hederacoside C ameliorates colitis via restoring impaired intestinal barrier through moderating S100A9/MAPK and neutrophil recruitment inactivation.

Authors:  Zheng-Xia Zha; Yu Lin; Ke-Xin Wang; Yan-Lin Zhang; Dan Li; Guo-Qiang Xu; Qiong-Ming Xu; Yan-Li Liu
Journal:  Acta Pharmacol Sin       Date:  2022-06-22       Impact factor: 7.169

2.  The role of AGEs in pathogenesis of cartilage destruction in osteoarthritis.

Authors:  Chao-Peng He; Cheng Chen; Xin-Chen Jiang; Hui Li; Li-Xin Zhu; Ping-Xiao Wang; Tao Xiao
Journal:  Bone Joint Res       Date:  2022-05       Impact factor: 4.410

Review 3.  Research Progress on the Antiosteoarthritic Mechanism of Action of Natural Products.

Authors:  Mingzhu Gao; Chun Chen; Qiaoyan Zhang; Jun Bian; Luping Qin; Leilei Bao
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-30       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.